Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA
PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.
PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.